Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chronic Lymphocytic Leukemia
- Diffuse Large B Cell Lymphoma
- Marginal Zone Lymphoma
- Small Lymphocytic Leukemia
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04189952
- Collaborators
- AstraZeneca
- Investigators
- Principal Investigator: Craig Moskowitz, MD University of Miami
Get Well Soon